Safety and Efficacy of AL-53817 Nasal Spray Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Nasal AllergiesAllergies
Interventions
DRUG

AL-53817 nasal spray solution

Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.

OTHER

Vehicle nasal spray

Inactive ingredients used as placebo comparator during Stage A and Stage B.

Trial Locations (1)

76134

Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY